Introduction {#S0001}
============

The Global Cancer Observatory estimates of the incidence of mortality and prevalence from major types of cancers such as lung, breast, and liver for 184 countries of the world revealed that there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer.[@CIT0001] By 2030, it is projected that there will be 26 million new cancer cases and 17 million cancer deaths per year.[@CIT0002] Besides, during the last decade, novel synthetic chemotherapeutic agents currently used for the treatment of cancer have not succeeded in fulfilling expectations despite the considerable cost of their development. Consequently, there is constant demand to develop new, target-specific, and affordable anticancer drugs.[@CIT0003]

Nanomedicine is the field of biomedical application of nanotechnology in which contrived nanoparticles (NPs) are used to treat diseases.[@CIT0004] Nanomedicine, with its innovative imaging and therapeutic competencies, has the prospective for early detection of cancer and cancer treatment.[@CIT0005] Nanomaterials can also be functionalized with biomolecules, to ensure target specificity, increasing the biocompatibility and characteristic of multifunctional.[@CIT0006] ZnO nanoparticles are nano-sized (less than 100 nm) particles and have a wide range of biomedical application such as cosmetics and facial products.[@CIT0007] ZnO nanoparticles are now being extensively researched for their anticancer properties. The effect of ZnO on the cytotoxic and apoptotic mechanism by releasing ZnO materials which induce cell death and it also suggest that requirement for ZnO dissolution for effective cytotoxicity.[@CIT0008] The main bioactive components of ginseng are triterpenoids collectively classified as ginsenosides. Among these ginsenosides, the metabolites of protopanaxadiol (PPD)-type ginsenosides are predominantly transformed into compound K (CK) and ginsenoside Rh2.[@CIT0009] These minor ginsenosides often exhibit superior pharmacological effects compared to their precursors.[@CIT0010] However, their clinical application is significantly limited due to their hydrophobic saponin backbone, poor bioavailability and absorption, and non-targeted cytotoxicity to normal cells.[@CIT0011] So biomolecular conjugations of ginsenosides with ZnO and drug delivery techniques play a significant role in solving these problematic issues.[@CIT0012]

Zinc is an obligatory trace element for humans and plays an important role in regulating cellular metabolism. The Food and Drug Administration (FDA) included ZnO in the list of generally recognized as a safe (GRAS) material based on their biodegradable, less toxic and easily absorbed by the body.[@CIT0013] Previous research stated that photocatalytic or photoluminescent effect of ZnONPs under light irradiation can produce reactive oxygen species (ROS) such as hydroxyl radicals and hydrogen peroxide which enable cell death and efficient decomposition of organic compounds.[@CIT0014] The objective of this study is to develop zinc oxide nanocarriers with ginsenoside by green synthesis. Zinc oxide nanoparticles help improve water dispersibility (poorly water-soluble ginsenosides), stability, and therapeutic effect agents that may elevate their capacities as effective anticancer agents. Zinc oxide (ZnO) nanocomposites functionalized by hyaluronic acid (HA) were prepared by a co-precipitation method (HA-ZnONcs), and the physiochemical properties of Rh2HAZnO were well characterized by spectroscopic analysis. In this study, we evaluated the potential effect of Rh2HAZnO nanoparticles to induce apoptotic-medicated cell death by damaging the nucleus and its materials in various human cancer cell lines, such as lung cancer (A549) cells, colon cancer (HT29) cells, and breast cancer (MCF7) cells. Elucidation of the effect of Rh2HAZnO on Caspase-9/p38 MAPK mediated pathway through upregulation of the gene and proteins by anticancer activity.

Experimental Section {#S0002}
====================

Materials And Methods {#S0002-S2001}
---------------------

The leaves of six-year-old *Dendropanax morbifera* Léveille and ginsenoside Rh2 (≥90%) were acquired from Ginseng Bank, Kyung Hee University (Yongin, Republic of Korea). High-molecular-weight sodium hyaluronate (HA, M~W~ = 1,280 kDa) was supplied by Xinjiang Fufeng Biotechnologies Co., Ltd. (Xinjiang, China). Zinc nitrate hexahydrate (reagent grade, ≥98%), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC, reagent grade, ≥98%), 4-(dimethylamino) pyridine (DMAP, ≥99%), hydrochloric acid (HCl, ACS reagent, 37%), and anhydrous *N,N*-dimethylformamide (DMF, ≥99%) were purchased from Sigma-Aldrich Chemicals (St. Louis, MO, USA). Phosphate buffer (20× PBS) was purchased from Biosesang (Seongnam, Republic of Korea). Trichloroacetic acid (TCA, ≥ 99%), potassium persulfate (≥98%), potassium ferricyanide (≥98%), sodium chloride (NaCl, ≥99.50%), and sodium hydroxide (NaOH, ≥98%) were purchased from Daejung Chemicals and Metals Co., Ltd. (Siheung, Republic of Korea). Glycerol was purchased from Junsei Chemical Co., Ltd (Tokyo, Japan). Iron (III) chloride hexahydrate (97%), methyl alcohol (MeOH, 95%), and ethyl alcohol (EtOH, 95%) were procured from Samchun Pure Chemical Co. Ltd. (Pyeongtaek, Republic of Korea). Other chemicals and reagents were purchased from commercial suppliers.

Synthesis And Characterization Of Rh2HAZnO {#S0002-S2002}
------------------------------------------

Synthesis of hyaluronic acid-functionalized ZnO (Rh2HAZnO) nanoparticle was prepared as per our previous study.[@CIT0012] The hyaluronic acid-functionalized ZnO was prepared by a NaOH-assisted co-precipitation method using zinc nitrate hexahydrate as a salt precursor and polymers as steric stabilizing agents. Aqueous leaf extract of *D. morbifera* was incorporated in the synthesis to enhance water stability and was synthesized as in a previous study, and the physiochemical properties were analyzed and reported.[@CIT0015] For characterization of nanoparticles, we have used scanning electron microscopy (SEM), and elemental mapping was performed. The previous study includes spectrophotometry (UV-Vis), field emission-transmission electron microscopy (FE-TEM), X-ray diffraction (XRD), zeta potential and hydrodynamic particle size of nanocomposites, and Fourier-transform infrared (FTIR) spectroscopy. Drug loading content of Rh2HAZnO was quantified by liquid chromatography-mass spectrometry (LC-MS), approximately 0.32 µg of ginsenoside Rh2 per 1 mg of Rh2-HA-ZnONcs was detected.

Photoluminescence Spectra {#S0002-S2003}
-------------------------

The photoluminescence (PL) spectra were measured at room temperature using the 325-nm line of a HeCd laser as the excitation source. Emitted light was collected by a lens and analyzed using a grating monochromator and a GaAs photomultiplier tube. Standard lock-in detection techniques were used to maximize the signal-to-noise ratio. The laser power for the PL excitation was about 5.66 W/cm^2^.

Total Internal Reflection Scattering (TIRS) {#S0002-S2004}
-------------------------------------------

The schematic representation and physical layout of the apparatus were modified from previously published protocols.[@CIT0016] The TIRS microscopy was carried out with upright Olympus BX51 microscope (Olympus Optical Co., Ltd., Tokyo, Japan) equipped with a 100× oil iris objective lens (NA = 0.6--1.3, UPLANFLN, Olympus Optical Co., Ltd., Tokyo, Japan). The smallest NA value (i.e., 0.6) was used for all the experiments. TIR illumination was conducted with a 30-mW, 637-nm laser (MGL-III-637-200 mW, Changchun New Industries Optoelectronics Tech. Co., Ltd., China) for illumination of the gold nanoparticles. A Uniblitz mechanical shutter (model LS3S2ZO-R3, Vincent Associates, Rochester, NY, USA) and a driver (model VMM-D1, Vincent Associates) were synchronized to an electron-multiplying cooled charge-coupled device (EMCCD) camera (512 × 512 pixel imaging array, QuantEM 512SC, Tucson, AZ, USA). The exposure time was 100 ms. Wavelength selection was accomplished with a central wavelength of 620/14 nm on an instrument purchased from Semrock (Rochester, NY, USA).

Cell Lines {#S0002-S2005}
----------

Human lung carcinoma (A549), human colon carcinoma (HT29), breast cancer (MCF7) cell lines and normal human keratinocytes (HaCaTs) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). All cell lines were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin, at 37 °C in 5% CO~2~.

Cell Viability Assay {#S0002-S2006}
--------------------

The cell cytotoxicity of Rh2HAZnO toward the various human cancer cell lines (A549, HT29, and MCF-7) was evaluated using an MTT assay. MTT stock solution (10×) (5 mg/mL) was dissolved in phosphate-buffered saline (PBS) (pH 7.4), filter sterilized and stored at −20 °C. We used 2 × 10^4^ cells per well (96-well plates) containing 100 μL of the complete culture medium. After 24 hrs, the test samples of different concentrations were added onto 96-well plates. The final concentration of DMSO Hybri-Max in all assays was less than 0.1%. Based on the preliminary test results, the anti-proliferative activity of Rh2HAZnO was determined with five to six concentrations ranging from 0 to 200 μg in 0.1% DMSO. The culture plates were incubated for 2 days in a 37 °C supplied with a humidified atmosphere of 5% CO~2~. The plates were then washed with 100 μL PBS, and 0.05% of 100 μL MTT reagent was added to each well and then incubated for 4 hrs as stated previously. MTT solution was removed, and 200 μL DMSO was added to each well. Finally, the plate was shaken in a microplate shaker for 10 mins in dark condition to dissolve the purple formazan crystals. The DMSO solution is used as a negative control. The optical density values were recorded using a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA) at a 560 nm and 670 nm, respectively. Blank values were subtracted from experimental values.

Reactive Oxygen Species (ROS) Generation {#S0002-S2007}
----------------------------------------

Free radical scavengers were analyzed by DPPH method, and intracellular ROS was measured by 2′,7′-dichlorodihydro-ﬂuorescein diacetate (DCFH-DA), as previously described.[@CIT0008] In brief, all three cell lines (2×10^5^/well) were treated with different concentrations of Rh2HAZnO (10 and 20 μg/mL) for 24 hrs. Then, 100 μL of DCFH-DA was added at 25 μM and incubated for 30 mins. Next, media were discarded and cells were washed twice with 1× PBS. The supernatant was kept in a 96-well plate in the dark, and the ﬂuorescence intensity was determined with a spectroﬂuorometer with excitation at 485 nm and emission at 520 nm.

Apoptosis Detection {#S0002-S2008}
-------------------

Hoechst-33258 staining was performed to capture the apoptotic induction of Rh2HAZnO in A549, HT29, and MCF7 cells. Cells were seeded into a 6-well plate at a density of 1 × 10^5^ cells/well in 2 mL medium and incubated at 37 °C with 5% CO~2~ overnight. The cells were then treated for 48 hrs and then stained with Hoechst-33258 solution at 2 μg/mL for 20 mins following our previous protocol. Scale bars were added using ImageJ software.

Quantitative Real-Time Reverse Transcription-PCR Analysis {#S0002-S2009}
---------------------------------------------------------

Treated and non-treated cultures of A549, HT29, and MCF7 cell monolayers grown in 25-cm^2^ cell culture flasks (Corning Costar, NY, USA) were treated with different concentrations of Rh2HAZnO (µg/mL). After 24 hrs of treatments, the total RNA was extracted from non-treated and treated cultures using the RNeasy mini kit (Qiagen, Hilden, Germany). For Real-time quantitative PCR (qRT-PCR), 500 ng of total RNA was reverse transcribed using oligo (dT) 15 primer (0.2 mM), and AMV Reverse Transcriptase (10 units/μL) and cDNA were synthesized using Superscript First-Strand Synthesis Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. qRT-PCR was performed in 96-well plate using 100 ng of cDNA in a 20 μL reaction volume using SYBR® Green Sensimix Plus Master Mix (Quantace, Watford, England). The melting point analysis of PCR products was carried out, which resulted in a single peak, indicating the presence of a single PCR product amplification. The thermal cycler conditions recommended by the manufacturer were used as follows: 10 mins at 95 °C, followed 40 cycles of 95 °C for 10 s, 58 °C for 10 s, and 72 °C for 20 s. The fluorescent product was detected at the last step of each cycle and measured in the real-time reverse transcriptase PCR thermocycler, and its genomic increase of the fluorescence corresponding to the exponential increase of the product was used to determine the threshold cycle (Ct) in each reaction using the formula 2−∆∆Ct (Livak & Schimittgen, 2001). The housekeeping gene encoding β-actin was used as a standard for all samples. All the real-time experiments were performed in triplicates, and statistical analysis was determined using Student's *t*-test.

Western Blotting {#S0002-S2010}
----------------

Three human cancer cell lines (2×10^5^/well) were treated with different concentrations (µg/mL) of Rh2HAZnO 0.1 mL DMSO for about 24 hrs. The cells were then harvested and washed twice with cold PBS. The cell pellets were lysed using RIPA lysis buffer (Sigma-Aldrich). The controls received 0.1% DMSO. The lysates were then centrifuged at 12,000 rpm for 20 mins at 4 °C. The protein content of the supernatant was determined using a Bradford Protein Assay kit, and BSA was used as the standard. The total proteins (15 μg) were mixed with an equal volume of 5× sample buffer containing 40 mM of DL-dithiothreitol, boiled for 10 mins, and then loaded onto 10% sodium dodecyl sulfate-polyacrylamide gels using a Mini-Protean 3 electrophoresis cell (Bio-Rad, Hercules, CA, USA). After electrophoresis at 150V for 1.5 hrs, the proteins from the gels were transferred onto a polyvinyl difluoride membrane (Pall Corporation, Pensacola, FL, USA) using an electroblotting apparatus. The membrane was then blocked with 5% skim milk (BD Difco, Franklin Lakes, NJ, USA) in PBS containing 0.1% (v/v) Tween-20 (PBS-T) at room temperature for 1 hr and further incubated overnight at 4 °C with a specific monoclonal or polyclonal antibody stated previously, each of them were used at a dilution of 1:1000 dilution. After washing with 0.1% PBS-T three times at 10-min intervals, the membranes were further incubated with a goat anti-rabbit IgG H&L (HRP) secondary antibody at a 1:5000 dilution for 2hrs RT. Finally, after washing with 0.1% PBS-T three times with a 10-min interval between washes, the blots were developed with an ECL chemiluminescence reagent and immediately exposed to a CP-PU X-ray film (AGFA, Mortsel, Belgium). The differences in protein expression were quantified using a Molecular Imager Gel Doc XR system (Bio-Rad, Hercules, CA, USA) and normalized to actin expression on the same membrane.

Statistical Analysis {#S0002-S2011}
--------------------

Results are expressed as mean ± SEM. The statistical signiﬁcance of differences between values was evaluated by one-way ANOVA. The statistical analysis was performed using Graph Pad 6.04 software (La Jolla, CA, USA). All experiments were performed at least in triplicate (n≤3) unless stated otherwise. Experimental data are reported as the means ± standard error (SEM). Statistical significances between control and sample groups were evaluated by Student's *t*-test with two-tailed distribution and two-sample equal variances. The extent of statistical significance was assigned by an increasing number of asterisks (\*P\<0.05, \*\*P\<0.01, and \*\*\*P\<0.001).

Results And Discussion {#S0003}
======================

Characterization Nanoparticles By SEM {#S0003-S2001}
-------------------------------------

The interactions of HA-ZnO with Rh2, PL spectroscopy was performed for the confirmation of the interaction. [Figure 1A](#F0001){ref-type="fig"} shows PL spectra of Rh2, HA-ZnO, and Rh2HAZnO, excited by a 325-nm laser line. The major PL peak of Rh2 is observed at \~410 nm, and the PL spectrum of Rh2 ranges widely from 350 to 650 nm. The PL spectrum of the HAZnO shows a new peak at 570 nm with a stoke shift of 210 nm, compared to the absorption band at 360 nm, as shown in [Figure 1A](#F0001){ref-type="fig"} (absorbance spectrum of HA-Zn nanoparticles). The PL intensity at 570 nm of HAZnO with Rh2 (Rh2HAZnO) is increased by about 2 times that of the HAZnO, while the PL intensity at 410 nm was almost unchanged. This observation means that HAZnO and Rh2 interacted with each other ([Figure 1A](#F0001){ref-type="fig"}). The surface morphology was analyzed by SEM and revealed that formation of Rh2HAZnO nanoparticles ([Figure 1B](#F0001){ref-type="fig"}). Element mapping confirmed the presence of Zn, oxygen, and carbon ([Figure 1C](#F0001){ref-type="fig"}--[F](#F0001){ref-type="fig"}).Figure 1Characterization of nanoparticles.**Notes:** (**A**) The photoluminescence (PL) spectra were measured at room temperature using the 325-nm line of a HeCd laser as the excitation source. Emitted light was collected by a lens and analyzed using a grating monochromator and a GaAs photomultiplier tube scanning electron microscope (SEM) images. (**B**) SEM images of Rh2HAZnO. (**C**) EDS spectrum of complete element distribution. (**D**--**F**) Element analytical maps of Zn, oxygen, and carbon.

To develop new anticancer therapies, the study of nanotechnology-based therapies for cancer has been increasing over the years.[@CIT0004] Nanotechnology-based therapies circulate in the bloodstream and are undetected by the immune system, which decreases the side effects associated with conventional anticancer treatments.[@CIT0017],[@CIT0018] The Rh2HAZnO characterized by X-ray diffraction pattern, FE-TEM, DLS, and FTIR spectra, several functional residues were implicated, such as O-H, C=O group of esters, N-H of amide groups, and C-C=C stretching. The PL spectra were measured at RT using the 325-nm line of a HeCd laser as the excitation source. Emitted light was collected by a lens and analyzed using a grating monochromator and a GaAs photomultiplier tube. Standard lock-in detection techniques were used to maximize the signal-to-noise ratio. The laser power for PL excitation was about 5.66 W/cm^2^. Based on HPLC result, the Rh2HAZnO contained the ginsenoside Rh2 ([[Figure S1](http://www.dovepress.com/get_supplementary_file.php?f=221328.tif)]{.ul}). As the PL value increases, the physical properties such as crystallinity, charge content, and carrier-forming ability increased while the transfer of ginsenoside Rh2 bound to this structure may affect the anticancer activity.[@CIT0019]

Analysis Of Mitochondria And Nucleus Staining Analysis {#S0003-S2002}
------------------------------------------------------

TIRS of Rh2HAZnO, which was used to treat lung cancer A549 cells, is presented in [Figure 2A](#F0002){ref-type="fig"}. In the dark field system, Rh2HAZnO accumulated on the cell surfaces after 3 hrs of treatment. Mito-Tracker analysis was performed with or without treatment of Rh2HAZnO for 24 hrs to detect the changes in mitochondria to predict apoptotic cell death--mediated pathway mechanism [Figure 2B](#F0002){ref-type="fig"}. At 10 and 20 µg/mL Rh2HAZnO treated cell lines showed significant bright fluorescence staining with damaged mitochondrial and intracellular debris with prominent stained nucleus indicated that Rh2HAZnO targeting mitochondrial mediated apoptosis by damaging the outer cellular membrane in A549 cells. Whereas, in control cell lines, there was no significant damage in intracellular organelles which indicated that no or less staining.Figure 2Total internal reflection scattering images (TIRS) and photoluminescence (PL) spectrum.**Notes:** (**A**) Total internal reflection scattering images (TIRS) of Rh2HAZnO which was treated for lung cancer A549. Lung cancer cell; zinc oxide; cell+ Rh2HAZnO. (**B**) Mito-Tracker and nucleus staining analysis after the treatment Rh2HAZnO nanoparticles.

In Vitro Cell Cytotoxicity Of Rh2HAZnO {#S0003-S2003}
--------------------------------------

For evaluation of apoptosis induction and potential antiproliferative effect of this nanoparticle, three different cancer cells were treated with Rh2, HAZnO and Rh2HAZnO for 24 hrs, respectively ([Figure 3A](#F0003){ref-type="fig"}--[C](#F0003){ref-type="fig"}). A significant reduction in cell viability was observed at 10 µg/mL in all three cell lines for Rh2HAZnO, respectively ([Figure 3D](#F0003){ref-type="fig"}). The reduced systemic toxicity of the drug-conjugated nano-formulation can be attributed to the presence of ginsenoside Rh2 in the nanocomposites. Based on the comparison of cell viability in the presence of Rh2, HAZnO, and Rh2HAZnO in A549 (lung), HT29 (colon), and MCF7 (breast) cancer cells, MCF-7 cell lines were the most inhibited by Rh2HAZnO. We also observed cytotoxicity of HA, Rh2, HAZnO and Rh2HAZnO with normal human keratinocytes (HaCaTs) ([Figure 3E](#F0003){ref-type="fig"}).Figure 3Cytotoxicity evaluation in cancer cells.**Notes:** Toxicity evaluation of ginsenoside Rh2, hyaluronic acid zinc nanoparticles (HAZnO), and Rh2HAZnO was assessed by MTT assay after 24 h. (**A**) Lung cancer (A549). (**B**) Colon cancer (HT29). (**C**) Breast cancer (MCF-7). (**D**) Comparison of cell viability in A549 (lung), HT29 (colon), and MCF7 (breast) cancer cells. (**E**) The cell viability of normal human keratinocytes (HaCaTs) was examined using MTT assay. Each bar represents the mean ± SE of duplicate samples of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared to the non-treated control. The difference was observed using Student's *t*-test.

Intracellular ROS Evaluation In Three Different Cancer Cell Lines {#S0003-S2004}
-----------------------------------------------------------------

To analyze the free radical scavenging by the treatment of Rh2HAZnO, DPPH assay was performed. It showed significant changes at 1.5mg/mL to compare with positive control gallic acid. For intracellular ROS evaluation, cells were treated with Rh2, HAZnO, and Rh2HAZnO for 24 hrs. The increase of ROS was probed by DCFH-DA ([Figure 4A](#F0004){ref-type="fig"}--[C](#F0004){ref-type="fig"}). Rh2HAZnO from the natural source has been reported to exhibit cell death in various cancer cells (A549, HT29, and MCF-7) through DNA damage by the generation of ROS and activation of multiple pro-apoptotic markers.[@CIT0020],[@CIT0021] The feature of ZnONPs is their capability to generate ROS at their surface, which can lead to cell death when the ROS levels exceed the antioxidant capacity of the cell. Therefore, ZnONPs have recently expanded prodigious interest in biomedical applications such as antibacterial and anticancer therapies. ROS generated on the surface of the ZnONPs, and particle dissolution and subsequent release of free Zn^2+^ ions that lead to ROS production within cells.[@CIT0022] Thus, determination of the antiproliferation effect of Rh2HAZnO was done through evaluation of with measurement of ROS level. Intracellular ROS production in cancer cell lines A549 ([Figure 4A](#F0004){ref-type="fig"}), HT29 ([Figure 4B](#F0004){ref-type="fig"}), and MCF7 ([Figure 4C](#F0004){ref-type="fig"}) was highly related to Rh2HAZnO. Several studies have reported the ability of various Rh2HAZnO synthesized from natural sources to induce toxicity in cancer cells. Likewise, the eco-friendly Rh2HAZnO could induce higher toxicity to cancer cells. Previously, it has been documented that the possible mechanisms of AgNP toxicity include induction of ROS, oxidative stress, DNA damage, and apoptosis in various cell lines.[@CIT0021] Oxidative stress is a known mechanism of nanomaterial-induced cell death in various types of cell lines.[@CIT0023]Figure 4Intracellular ROS evaluation in three cancer cell lines.**Notes:** Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs, and the increase of ROS was probed by DCFH-DA. Scale bar = 10 μm. (**A**) Lung cancer (A549). (**B**) Colon cancer (HT29). (**C**) Breast cancer (MCF-7). Each bar represents the mean ± SE of duplicate samples of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared to the non-treated control. The difference was observed using student's *t*-test.

Rh2HAZnO Caused Nuclear Damage To Cancer Cells {#S0003-S2005}
----------------------------------------------

A549, HT29, and MCF-7 cancer cells were monitored after different concentrations of Rh2HAZnO treatment by performing Hoechst-33258 staining. In untreated cells, the cell wall remains intact, and the Hoechst dye remains impermeable and thus caused reduced staining of cells. Whereas, when the cells were treated with Rh2HAZnO, the cell walls of cancer cells damaged due to the penetration of the dye into the cells and showed positive apoptotic cells ([Figure 5A1](#F0005){ref-type="fig"}, [B1](#F0005){ref-type="fig"}, and [C1](#F0005){ref-type="fig"}). The results showed that gradual increase in morphological alteration reached its maximum when cells were treated with a high concentration of Rh2HAZnO. In addition, the cell size and number were also significantly reduced, which is evident that Rh2HAZnO resulted in the detachment of cells and caused alternation in morphology.Figure 5Evaluation of apoptosis in three cancer cell lines.**Notes:** Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs. Hoechst stained positive apoptotic cells are indicated with white arrows (**A1, B1**, and **C1**). Scale bar = 10 μm. Relative gene expression was evaluated by RT-PCR (**A2**--**C2** and **A3**--**C3**), and band density was analyzed with ImageJ software. (**A1**--**A3**) Lung cancer (A549). (**B1**--**B3**) Colon cancer (HT29). (**C1**--**C3**) Breast cancer (MCF-7). Each bar represents the mean ± SE of duplicate samples of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared to the non-treated control. ^++^*P* \< 0.01, and ^+++^*P* \< 0.001 compared HAZnO with Rh2HAZnO. The difference was observed using Student's *t*-test.

Rh2HAZnO Treatment Induced Apoptosis Of Cancer Cells {#S0003-S2006}
----------------------------------------------------

Lung cancer (A549), colon cancer (HT29), and breast cancer (MCF-7) cells were treated with Rh2, HAZnO and Rh2HAZnO to induce nuclear cell death by involving apoptotic mechanism by upregulating the caspase-9/activation of stress-responsive mitogen-activated protein kinases (MAPKs) gene expression such as phosphorylation of p38. The antiapoptotic member, BCL2, and the proapoptotic member, BAX, have been proven to be one of the most critical players in the intrinsic apoptosis pathway.[@CIT0024],[@CIT0025] The ratio of BAX/BCL2 is a key factor regulating apoptosis.[@CIT0026] The ratio BAX/BCL2 significantly increased in both A549 and HT29 cancer cells ([Figure 5A3](#F0005){ref-type="fig"} and [B3](#F0005){ref-type="fig"}), while the BAX/BCL2 ratio did not show significant differences in MCF-7 cancer cells ([Figure 5C3](#F0005){ref-type="fig"}).

Caspases (cysteine-aspartic acid proteases) play a vital role in the apoptosis process through activation of caspase cascades including the initiation of caspase-9.[@CIT0027] A previous study demonstrated that application of pseudo-G-Rh2 induced intrinsic-mediated apoptosis in A549 cells by activation of p53 and caspase-9.[@CIT0028] Expression change of p53 correlated with expression change of two downstream BCL2 family proteins, BAX and BCL2. This observation agrees with the transcriptional expression change of p53 in those three cell lines.

The expressions of *CASP7, CASP9*, and *p53* in A549 cell line were analyzed by performing qPCR ([Figure 6](#F0006){ref-type="fig"}). The expressions of *CASP9* and *p53* genes tend to increase in A549 cells that are gradually with Rh2 or HAZnO. Moreover, cells treated with Rh2HAZnO nanoparticles further upregulated both *CASP9* and *p53* transcripts ([Figure 6C](#F0006){ref-type="fig"} and [D](#F0006){ref-type="fig"}). In contrast, the expression of p53 through Western blot analysis did not exhibit increased p53 accumulation, but the cells undergo apoptosis through activation of CASP9 rather than p53 itself ([Figure 6D](#F0006){ref-type="fig"}). Expression of the *MAPK* gene and phosphorylation of the p38 MAPK protein were found no significant difference in A549 cell lines except cleaved PARP (Asp 214) protein.Figure 6Potential apoptotic mechanism of Rh2HAZnO in A549 lung cancer cells.**Notes:** Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs (**A**). The relative analysis was analyzed with ImageJ software (**B**--**D**). Protein expression was evaluated by Western blotting (**E**). Each bar represents the mean ± SE of duplicate samples of three independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared to the non-treated control. ^+++^*P* \< 0.001 compared HAZnO with Rh2HAZnO. The difference was observed using Student's *t*-test.

To determine the potential apoptotic mechanism of Rh2HAZnO in HT29 colon cancer cells, the relative gene expression and the protein expression were assessed. Upon Rh2 treatment, p53 expression was steadily down-regulated by up to 0.45-fold in the HT29 colon cancer cell line. Interestingly, gene and protein expression tend to increase when cells are treated with HAZnO, and the highest expression pattern was recorded when cells were treated with Rh2HAZnO ([Figure 7A](#F0007){ref-type="fig"}, [E](#F0007){ref-type="fig"}, and [G](#F0007){ref-type="fig"}). The expression of p21 was gradually downregulated when cells were treated with Rh2, HAZnO or Rh2HAZnO, which clearly shows that HT29 cells undergo p53-mediated apoptosis ([Figure 7](#F0007){ref-type="fig"}). Ginsenosides Rh2 and Rd inhibit the growth of HT29 cells through activation of apoptosis processes.[@CIT0029] A previous study in HCT116 colon cancer cells demonstrated that Rh2 induced apoptosis through activation of p53.[@CIT0030]Figure 7Potential apoptotic mechanism of Rh2HAZnO in HT29 colon cancer cells.**Notes:** Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs. Relative gene expression was evaluated by RT-PCR (**A**), and band density analysis was done with ImageJ software (**B**--**F**). Protein expression was evaluated by Western blotting (**G**). Each bar represents the mean ± SE of duplicate samples of three independent experiments. \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared to the non-treated control. ^++^*P* \< 0.01, and ^+++^*P* \< 0.001 compared HAZnO with Rh2HAZnO. The difference was observed using Student's *t*-test.

For the detection of apoptosis in MCF7 breast cancer cells, relative gene expressions of p53 and the cleaved CASP3, 7, 9 were evaluated through Western blot analysis ([Figure 8](#F0008){ref-type="fig"}). Activation of CASP7 and CASP9 pathways has been identiﬁed to play an essential role in apoptosis, especially during apoptotic chromatin condensation and DNA fragmentation in various cell lines. Furthermore, the anti-proliferative effect of Rh2HAZnO has been found to be related to activation of p38 MAPK, CASP9 genes, p38 MAPK, and CASP9 proteins during treatment, as a result of the morphological changes in the nuclei of MCF7 cells along with the cytotoxic effect and induction of oxidative stress. The expression of p53 through Western blot analysis did not show increased p53 accumulation, indicating that MCF7 cells undergo apoptosis through activation of CASP7 and CASP9 rather than p53 itself ([Figure 8B](#F0008){ref-type="fig"}, [C](#F0008){ref-type="fig"}, and [E](#F0008){ref-type="fig"})Figure 8Potential apoptotic mechanism of Rh2HAZnO in MCF-7 breast cancer cells.**Notes:** Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs. Relative gene expression was evaluated by RT-PCR (**A**), band density analysis was analyzed with ImageJ software (**B**--**D**). Protein expression was evaluated by Western blotting (**E**). Each bar represents the mean ± SE of duplicate samples of three independent experiments. \*\**P* \< 0.01, and \*\*\**P* \< 0.001 compared to the non-treated control. ^+++^*P* \< 0.001 compared HAZnO with Rh2HAZnO. The difference was observed using Student's *t*-test.

The proposed mechanism of inducing apoptosis is illustrated in [Figure 9](#F0009){ref-type="fig"}. The cytotoxicity effect of Rh2HAZnO is postulated from triggering intracellular reactive oxygen species (ROS), which was observed in three different cancer cells ([Figure 4](#F0004){ref-type="fig"}). The photoluminescent effect of ZnO initiates electron transmission from the valence band to the conduction band, thus creating an electron--hole pair. The hole can induce a sequence of photochemical reactions to generate ROS at the NP surface in an aqueous suspension.^70^ ROS generation by ZnONPs upon irradiation with UV light has been utilized for photo-triggered anticancer and antibacterial activities via ROS-induced damage to cell membranes, mitochondria, proteins, and DNA.[@CIT0031] The tumor suppressor protein p53 is a redox-active transcription factor that organizes cellular responses upon a range of stresses including intracellular induction of ROS.[@CIT0032] The increase in intracellular ROS is associated with the magnitude of p53 protein expression,[@CIT0033] which was also shown in the lung cancer A549 cells ([Figure 6D](#F0006){ref-type="fig"}) and the colon cancer HT29 cells ([Figure 7D](#F0007){ref-type="fig"}) while the opposite trend was observed in the breast cancer MCF-7 cells ([Figure 8D](#F0008){ref-type="fig"}).Figure 9The proposed mechanism of the apoptotic effect of Rh2HAZnO on the three different cancer cells: A549 (lung), HT29 (colon), and MCF7 (breast) cancer cells.

The increasing ratio BAX/Bcl-2 results in the formation of apoptosome and activation of its effector, CASP9,[@CIT0034],[@CIT0035] which was indicated as the increased transcriptional expression of *CASP9* in A549, HT29, and MCF-7 cancer cells ([Figures 6C](#F0006){ref-type="fig"}, [7D](#F0007){ref-type="fig"}, and [8C](#F0008){ref-type="fig"}). The activation of CASP9 contributed to the activation of CASP7 in MCF-7 cells ([Figure 8B](#F0008){ref-type="fig"}). Since CASP7 is one of the two effectors of mitochondrial events of apoptosis,[@CIT0036],[@CIT0037] the series of expressional change of apoptosis-related proteins indicated that the ROS stress induced by Rh2HAZnO results in mitochondria-mediated apoptosis. This postulation was also confirmed with an increase of cleaved PARP in the HT29 colon cancer cells.

Our data for the first time showed that Rh2HAZnO inhibits the proliferation of cancer cells by inducing apoptotic-mediated cell death. This result suggests that Rh2HAZnO might serve as a potential antitumor agent against various cancer cells with further proper in vivo experimental analysis.

Conclusion {#S0004}
==========

In this study, we evaluate the potential of Rh2HAZnO to induce apoptosis and DNA damage in lung cancer (A549), colon cancer (HT29), and breast cancer (MCF7) cells, respectively. It has been identified that, among different caspase pathways, activation of the caspase-9 pathway is required for apoptosis by Rh2HAZnO. Furthermore, the effects of Rh2HAZnO on Caspase-9/p38 MAPK markers were elucidated for anticancer activity.
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